EcoDrugPlus

Retinoid X Receptor Beta

Ensembl ID : ENSPTXG00000016800
Gene Symbol: RXRB
1 Cross references
234 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Retinoid X Receptor Gamma

Ensembl ID : ENSPTXG00000000087
Gene Symbol: RXRG
1 Cross references
274 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L10

Ensembl ID : ENSPTXG00000007999
Gene Symbol: RPL10
2 Cross references
408 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L11

Ensembl ID : ENSPTXG00000001747
Gene Symbol: RPL11
3 Cross references
170 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L12

Ensembl ID : ENSPTXG00000015042
Gene Symbol: RPL12
3 Cross references
452 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L13

Ensembl ID : ENSPTXG00000010096
Gene Symbol: RPL13
3 Cross references
271 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L13a

Ensembl ID : ENSPTXG00000015578
Gene Symbol: RPL13A
2 Cross references
365 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L14

Ensembl ID : ENSPTXG00000012511
Gene Symbol: RPL14
3 Cross references
308 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L18

Ensembl ID : ENSPTXG00000011801
Gene Symbol: RPL18
3 Cross references
379 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L18a

Ensembl ID : ENSPTXG00000007481
Gene Symbol: RPL18A
3 Cross references
370 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L19

Ensembl ID : ENSPTXG00000008434
Gene Symbol: RPL19
3 Cross references
312 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L21

Ensembl ID : ENSPTXG00000005331
Gene Symbol: RPL21
3 Cross references
776 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).